Mylan Pushes All Major U.S. Med Launches to 2018, Cites Slow FDA Approvals

Aug 09, 2017

Mylan have announced major delays for two of its key drugs, a generic version of GlaxoSmithKline's Advair and Teva's Copaxone, which have caused the company to lower its projections for this year and next.

According to Mylan, it will not be launching any major U.S. products this year, citing an uncertain U.S. regulatory environment while it expressed frustration at the U.S. Food and Drug Administrations slow pace of drug approval.

Mylan also said that it expects single digit generic drug price erosion worldwide. 

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments